BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature
. Although lipid-lowering therapy (LLT) has improved in the last few years, most FH patients do not achieve an optimal therapeutic LDL cholesterol (LDL-C) level (8) and therefore remain at high risk for premature ASCVD.
International guidelines consider FH patients at high cardiovascular risk; therefore, the optimal LDL-C goal should be <100 mg/dl or <70 mg/dl with previous history of ASCVD, or at least a 50% reduction in LDL-C levels (9,10). Nevertheless, based on longitudinal studies, little is known about the use of LLT and the attainment of LDL-C goals and its determinants in real clinical practice. National registries can be utilized to provide this key information, necessary for improving models of care for FH, including physician and patient education, therapeutic protocols, health policy, and planning (11, 12) . SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) was designed to improve insight into the prognostic factors, treatments, and mechanisms that influence the development of ASCVD and mortality in a welldefined FH population.
Our aim was to use information accrued by the SAFEHEART registry to investigate the achievement of LDL-C goals in relation to the use of LLT over time, as well as to assess factors that predict the likelihood of attaining these goals.
METHODS
The SAFEHEART study is an open, multicenter, nationwide, long-term prospective cohort study in a molecularly defined, heterozygous FH population in Spain (13 Treatment goals were initially defined according to consecutively released international guidelines (9, 10, 14) . These guidelines were used to inform, educate, and train physicians who participated by including patients and families in this registry; details of best practices were reinforced at every annual meeting of the Fundación Hipercolesterolemia Familiar attended by relevant physicians. An electronically based and telephone advice system was also used to inform care, and a web-based training program was deployed to further support management.
A coordinating center based in Madrid was responsible for managing case follow-up. Patients were contacted annually using a standardized phone call to record relevant changes in lifestyle habits and medications, and development of cardiovascular events. Premature ASCVD was defined as the occurrence of the first event before 55 years of age in men and before 65 years of age in women. The same age thresholds were used to define premature familial ASCVD.
CLINICAL AND LABORATORY MEASUREMENTS.
Demographic and clinical characteristics were recorded as described elsewhere and included age, classic cardiovascular risk factors, physical examination, and current treatment for hypercholesterolemia and other risk factors (13) . Venous blood samples were taken after 12 h of fasting. Serum, plasma, and deoxy- of Lp(a) mass in mg/dl was cholesterol. DNA was isolated from whole blood using standard methods, and the genetic diagnosis of FH was made using a DNA microarray (15) . Mutations were classified as previously described (5). 
RESULTS
We recruited 4,132 subjects, 769 of whom were index cases (18.6%). Of the total population, 3,745 were $18 years of age and 2,752 were FH cases (at-entry Perez de Isla et al.
The SAFEHEART Registry A reduction in the number of current smokers from 26.3% to 15.8% was observed. Thirteen patients developed T2DM, and 28 patients were diagnosed with high blood pressure during follow-up. There were significant reductions in the plasma concentrations of TC, LDL-C, and non-HDL-C; a significant increase in HDL-C was also observed ( Table 2) .
LLT, FUNCTIONAL MUTATIONS, AND GOAL ATTAINMENT.
We identified 209 different functional mutations in LDLR (97.0%) and apo-B (3.0%) genes, of which 33%
were classified as null mutations, 50% as defective mutations, and 17% as unknown mutations. Values are median (interquartile range).
Abbreviations as in Table 1 . Values are n (%). A negative sign indicates not present; a plus sign indicates present.
LLT ¼ lipid lowering therapy; other abbreviations as in Table 1 . Perez de Isla et al.
The SAFEHEART Registry
DISCUSSION
We report the characteristics, LLT use, and attain- Despite a high percentage receiving maximal lipid-lowering therapy, most familial hypercholesterolemia (FH) patients still have high low-density lipoprotein cholesterol (LDL-C) levels and did not achieve the recommended LDL-C target for patients (A) with or (B) without cardiovascular disease (CVD). There is a clinical need for new lipid-lowering treatments in combination with current therapy to reach lower LDL-C levels in an effort to prevent the development of premature atherosclerotic cardiovascular disease.
Perez de Isla et al. patients (8) . However, another cross-sectional study with genetically defined FH patients, most of them managed in a primary care setting, showed LDL-C levels <100 mg/dl in 12.2% of patients, more similar to our study (18) . In a study performed in 5 centers in France (32.2% genetically characterized), only 10.4%
reached LDL-C <100 mg/dl levels despite maximal treatment (19) . With regard to the type of mutation, in a recent work, 22% of patients with a null mutation and 27.1% patients with a defective mutation had an LDL-C value <130 mg/dl (20) . Furthermore, a large, randomized clinical trial in patients at high cardiovascular risk with severe hypercholesterolemia found that patients with FH on dual therapy (atorvastatin 40 mg and ezetimibe 10 mg) were approximately 4 times more likely to achieve an LDL-C level <100 mg/dl compared with those on monotherapy (atorvastatin 40 mg) (17% vs. 4%, respectively) (21). The SAFEHEART Registry M A R C H 2 2 , 2 0 
